- Home
- ACET vs ATRA Comparison
ACET vs ATRA Comparison
Compare ACET & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- ATRA
- Stock Information
- Founded
- ACET 1947
- ATRA 2012
- Country
- ACET United States
- ATRA United States
- Employees
- ACET N/A
- ATRA N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACET Health Care
- ATRA Health Care
- Exchange
- ACET Nasdaq
- ATRA Nasdaq
- Market Cap
- ACET 60.5M
- ATRA 67.9M
- IPO Year
- ACET N/A
- ATRA 2014
- Fundamental
- Price
- ACET $0.72
- ATRA $12.05
- Analyst Decision
- ACET Strong Buy
- ATRA Strong Buy
- Analyst Count
- ACET 7
- ATRA 3
- Target Price
- ACET $5.60
- ATRA $21.00
- AVG Volume (30 Days)
- ACET 679.5K
- ATRA 50.7K
- Earning Date
- ACET 08-07-2025
- ATRA 08-11-2025
- Dividend Yield
- ACET N/A
- ATRA N/A
- EPS Growth
- ACET N/A
- ATRA N/A
- EPS
- ACET N/A
- ATRA 0.56
- Revenue
- ACET N/A
- ATRA $188,667,000.00
- Revenue This Year
- ACET N/A
- ATRA N/A
- Revenue Next Year
- ACET N/A
- ATRA N/A
- P/E Ratio
- ACET N/A
- ATRA $21.39
- Revenue Growth
- ACET N/A
- ATRA 202.41
- 52 Week Low
- ACET $0.45
- ATRA $5.01
- 52 Week High
- ACET $1.63
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- ACET 52.09
- ATRA 55.38
- Support Level
- ACET $0.64
- ATRA $11.86
- Resistance Level
- ACET $0.78
- ATRA $12.76
- Average True Range (ATR)
- ACET 0.06
- ATRA 0.83
- MACD
- ACET 0.01
- ATRA -0.02
- Stochastic Oscillator
- ACET 68.33
- ATRA 53.39
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).